Prediction of Pharmacokinetic Drug–Drug Interactions Involving Anlotinib as a Victim by Using Physiologically Based Pharmacokinetic Modeling
Based on the PBPK modeling, there is a low risk of DDI between anlotinib and potent CYP3A/1A2 inhibitors, but caution and enhanced monitoring for adverse reactions are advised. To mitigate the risk of anti-tumor treatment failure, it is recommended to avoid concurrent use of strong CYP3A inducers. In conclusion, our study enhances understanding of anlotinib's interaction with medications, aiding scientists, prescribers, and drug labels in gauging the expected impact of CYP3A/1A2 modulators on anlotinib's pharmacokinetics.
Authors
- Qingfeng He (ORCID: https://orcid.org/0000-0001-5795-1550)
- Yong‐Soon Cho
- Xiaoqiang Xiang (ORCID: https://orcid.org/0000-0002-8683-2603)
- Howlader Saurav
- Xiaowen Wang (ORCID: https://orcid.org/0000-0003-4623-1608)
- Dong‐Hyun Kim (ORCID: https://orcid.org/0000-0003-4783-7900)
- Fengjiao Bu (ORCID: https://orcid.org/0000-0003-2080-261X)
- Mingshe Zhu
- Jae Gook Shin
Institutions
- Inje University (KR)
- Fudan University (CN)
- Quzhou City People's Hospital (CN)
- Eye & ENT Hospital of Fudan University (CN)
- Ocean Power Technologies (United States) (US)
- Quzhou University (CN)
Publication Details
- Journal
- Drug Design Development and Therapy
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/dddt.s480402
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57